FindTrial
Sign In

Objective Study of DEP regimen of Efficacy and Safety in hemophagocytic lymphohistiocytosis patients

Objective Study of DEP regimen of Efficacy and Safety in hemophagocytic lymphohistiocytosis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015283
Enrollment
Unknown
Registered
2018-03-20
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemophagocytic lymphohistiocytosis

Interventions

Case series:DEP regimen chemotherapy

Sponsors

the First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who meet HLH-2004 diagnostic criteria

Exclusion criteria

Exclusion criteria: 1. Heart function above grade II (NYHA); 2. Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2; 3. Pregnancy or lactating Women; 4. Allergic to Liposomal doxorubicin or etopside; 5. Active bleeding of the internal organs; 6. Participate in other clinical research at the same time.

Design outcomes

Primary

MeasureTime frame
ferritin;soluble CD52;neutrophil;hemoglobin;thrombocyte;triglyceride;glutamic-pyruvic transaminase;Fibrinogen;—

Contacts

Public ContactLi Fei

the First Affiliated Hospital of Nanchang University

wxh_ndyfy@163.com+86 13970038386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026